Chinese pharmaceutical company Huajian Medical has put on hold its substantial cryptocurrency acquisition plan, initially unveiled in mid-August. The plan had been set to acquire up to 3 billion yuan worth of digital currency contingent on shareholder approval. However, despite the anticipated circular being submitted to shareholders, no progress has been made for over two and a half months. The company stated that additional time is required to secure shareholder authorization before proceeding with the acquisition. Huajian Medical intends to disclose any future Ethereum (ETH) purchases in accordance with the Hong Kong Stock Exchange’s listing rules, specifically Chapter 14 which mandates transparency regarding transactions. In parallel, the company plans to develop an AI algorithm platform for enhanced asset valuation models, aiming to improve accuracy and transparency within their distribution network and securitization processes.